PRKDC and renal cell carcinoma: When analyzing DNA-PKcs activity using a previously-described assay [22], we found that CC-115 treatment (5 μM, 2h) significantly inhibited DNA-PKcs activity in 786-O and primary RCC cells (“RCC1/2”) (Figure 3A).